Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Seeks Partners For Biosimilars, Oncology Research

FY22 Guidance Lowered

Executive Summary

Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.

You may also be interested in...



FDA Inspection Vista Amid COVID-19, How Things Are Poised For Indian Firms

The US FDA conducted seven drug inspections in India from February through August 2021 and front-line Indian firms are hopeful things will pick up further and that some pre-approval inspections may happen virtually. But no foreign surveillance inspections are expected to be conducted by FDA inspectors traveling from the US before September 2021.

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Glenmark Fulfills Promise To Introduce Tiotropium In Europe

India’s Glenmark had noted recently that market entry was forthcoming for a generic Boehringer Ingelheim’s Spiriva Handihaler, and has now delivered with an initial UK launch.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel